Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review

Glauco Valdivieso-Jiménez, Dennis Anthony Pino-Zavaleta, Susan K. Campos-Rodriguez, Brando Ortiz-Saavedra, María F. Fernández, Vicente Aleixandre Benites-Zapata

Research output: Contribution to journalReview articlepeer-review


Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed.

Original languageEnglish
Pages (from-to)541-557
Number of pages17
JournalPsychiatric Quarterly
Issue number4
StatePublished - Dec 2023


  • Aripiprazole
  • Borderline personality disorder
  • Systematic review (MeSH)


Dive into the research topics of 'Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review'. Together they form a unique fingerprint.

Cite this